TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03005522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral dexamethasone
Description: Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: dosed with placebo
Study: NCT04064632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine + darunavir/cobicistat
Description: Switch to a dual ART

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine + darunavir/cobicistat
Description: Switch to a dual ART
Study: NCT02793453

Intervention type: OTHER
Group type: OTHER
Intervention: periodontal smears

Intervention type: OTHER
Group type: OTHER
Intervention: periodontal smears
Study: NCT04097600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
Study: NCT02107690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low temperature lidocaine injection
Description: 4 °C

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room temperature lidocaine injection
Description: 20 °C

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body temperature lidocaine injection
Description: 37 °C
Study: NCT04221425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality rehabilitation system (VRRS)
Description: experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
Study: NCT02767310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg film-coated tablets
Description: Single oral dose of 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20 mg film-coated tablets
Description: Single oral dose of 20 mg
Study: NCT02992093

Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites

Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
Study: NCT00979732

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grape seed extract
Description: grape seed extract 150 mg twice a day (BID) in beverage or capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: grape seed extract placebo
Description: grape seed extract 150 mg twice a day (BID) in beverage or capsule form
Study: NCT02563808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Decision Aid
Description: Females will receive standard decisions aid for early stage breast cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-surgical Regret Decision Aid
Description: Females will receive anticipated regret-augmented version for early breast cancer.
Study: NCT03021538

Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: ECMO is used during lung transplant procedure

Intervention type: DEVICE
Intervention: Cardiopulmonary Bypass
Description: CPB is used during lung transplant procedure
Study: NCT01356849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
Study: NCT03469297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brown Glaucoma Implant
Description: The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
Study: NCT03416647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenojejunostomy
Description: Duodenojejunostomy with or without duodenal resection
Study: NCT01767298

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: Valsartan alone

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide alone
Study: NCT04901221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extrusion arch
Description: one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
Study: NCT00936260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment
Study: NCT01678547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted walking
Description: The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ground treatment
Description: The practice will included ground walking therapy s for 40 min with therapist support.
Study: NCT02979015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT04338269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
Study: NCT01776840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Study: NCT04138277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT2221
Description: Participants received ATB200 co-administered with AT2221 (Miglustat)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATB200
Description: Enzyme Replacement Therapy via intravenous infusion
Study: NCT04910230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
Study: NCT00205049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: daily dosing
Study: NCT01327963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral Incisionless Fundoplication
Description: Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
Study: NCT02367638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111
Description: Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: VARIVAX is administered by subcutaneous injection
Study: NCT01123681

Intervention type: DEVICE
Intervention: Choice of endotracheal tube
Description: Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration

Intervention type: DEVICE
Intervention: Choice of endotracheal tube
Description: Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
Study: NCT04680364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partnered dance
Description: Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
Study: NCT03395444

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pulsed shortwave therapy
Description: Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed shortwave therapy
Description: Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
Study: NCT02016612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seri Surgical Scaffold
Description: An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seri Surgical Scaffold
Description: An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seri Surgical Scaffold
Description: An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seri Surgical Scaffold
Description: An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
Study: NCT03450070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy Mask Cream
Description: test panel
Study: NCT00359164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
Description: Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Study: NCT04234100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice rich in hesperidin and narirutin
Description: The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
Study: NCT01866449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study: NCT02921737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
Study: NCT04406753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques in C0-1 and C2-3 with cervical exercise
Description: Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Exercise
Description: This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets.
Study: NCT04629404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Study: NCT03678038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (Shincort) injection to rotator interval
Description: via rotator interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Shincort) injection to posterior glenuhumeral recess
Description: via posterior glenuhumeral recess
Study: NCT01806805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonegran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zonegran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03595657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001
Description: monoclonal antibody
Study: NCT04324580

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Formal Physical Therapy
Description: Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self directed physical therapy
Description: Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft dressing (No Splint)
Description: Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
Study: NCT01233505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03733925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.